LeMaitre Vascular, Inc. (NASDAQ:LMAT) Stake Increased by Franklin Resources Inc.

Franklin Resources Inc. raised its stake in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 5.2% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 12,646 shares of the medical instruments supplier’s stock after acquiring an additional 627 shares during the quarter. Franklin Resources Inc. owned approximately 0.06% of LeMaitre Vascular worth $1,165,000 at the end of the most recent quarter.

Several other hedge funds also recently added to or reduced their stakes in LMAT. Bank of New York Mellon Corp lifted its position in shares of LeMaitre Vascular by 2.5% during the second quarter. Bank of New York Mellon Corp now owns 210,599 shares of the medical instruments supplier’s stock worth $17,328,000 after purchasing an additional 5,213 shares during the last quarter. Allspring Global Investments Holdings LLC lifted its holdings in LeMaitre Vascular by 61.3% during the 2nd quarter. Allspring Global Investments Holdings LLC now owns 9,202 shares of the medical instruments supplier’s stock worth $757,000 after buying an additional 3,498 shares during the last quarter. Van ECK Associates Corp acquired a new position in shares of LeMaitre Vascular in the 2nd quarter worth approximately $75,000. nVerses Capital LLC increased its holdings in shares of LeMaitre Vascular by 33.3% in the 2nd quarter. nVerses Capital LLC now owns 800 shares of the medical instruments supplier’s stock valued at $66,000 after acquiring an additional 200 shares during the last quarter. Finally, Versor Investments LP acquired a new stake in shares of LeMaitre Vascular during the 2nd quarter valued at approximately $387,000. 84.64% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research firms have weighed in on LMAT. StockNews.com lowered shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a research note on Friday, December 13th. Oppenheimer reiterated an “outperform” rating and set a $93.00 price objective (up previously from $90.00) on shares of LeMaitre Vascular in a research note on Friday, November 1st. Barrington Research lifted their target price on LeMaitre Vascular from $92.00 to $93.00 and gave the company an “outperform” rating in a research note on Friday, November 1st. Finally, Cantor Fitzgerald started coverage on LeMaitre Vascular in a research report on Tuesday, October 15th. They set a “neutral” rating and a $96.00 price target on the stock. Three research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, LeMaitre Vascular has an average rating of “Moderate Buy” and an average target price of $94.57.

Insider Transactions at LeMaitre Vascular

In other news, Director Bridget A. Ross sold 3,750 shares of the business’s stock in a transaction on Friday, November 15th. The stock was sold at an average price of $101.47, for a total value of $380,512.50. Following the sale, the director now owns 2,278 shares of the company’s stock, valued at approximately $231,148.66. The trade was a 62.21 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 10.79% of the company’s stock.

LeMaitre Vascular Trading Down 1.3 %

LMAT opened at $92.84 on Friday. LeMaitre Vascular, Inc. has a twelve month low of $52.88 and a twelve month high of $109.58. The stock has a market cap of $2.09 billion, a PE ratio of 50.73, a price-to-earnings-growth ratio of 2.47 and a beta of 0.93. The business’s 50 day moving average is $97.93 and its 200-day moving average is $90.51.

LeMaitre Vascular (NASDAQ:LMAT) last announced its quarterly earnings results on Thursday, October 31st. The medical instruments supplier reported $0.49 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.44 by $0.05. LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. The company had revenue of $54.82 million during the quarter, compared to analyst estimates of $53.50 million. During the same quarter in the previous year, the firm posted $0.33 EPS. The firm’s quarterly revenue was up 15.6% on a year-over-year basis. As a group, analysts forecast that LeMaitre Vascular, Inc. will post 1.94 EPS for the current year.

LeMaitre Vascular Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, December 5th. Shareholders of record on Thursday, November 21st were given a dividend of $0.16 per share. The ex-dividend date of this dividend was Thursday, November 21st. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.69%. LeMaitre Vascular’s dividend payout ratio (DPR) is 34.97%.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.